Dataset from A Phase 3 Study Comparing Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy With Both Lenalidomide and a Proteasome Inhibitor.
收藏NIAID Data Ecosystem2026-05-10 收录
下载链接：
https://doi.org/10.25934/PR00009368
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to evaluate the effects of the addition of daratumumab to
pomalidomide and dexamethasone in terms of progression-free survival in subjects with
relapsed or refractory Multiple Myeloma.
创建时间：
2026-04-09
